|Bid||6.27 x 1800|
|Ask||6.28 x 1800|
|Day's range||5.84 - 6.58|
|52-week range||3.21 - 9.36|
|Beta (5Y monthly)||0.11|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs initiated coverage on Iovance stock with a buy recommendation. Investors no doubt liked Goldman Sachs' 12-month price target of $12 for Iovance.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript November 7, 2023 Iovance Biotherapeutics, Inc. reports earnings inline with expectations. Reported EPS is $-0.46 EPS, expectations were $-0.46. Operator: Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2023 Financial Results and Corporate Update Conference Call. My name is Abigail, and I will be your […]
On a brutal day for biotech stocks, Iovance Biotherapeutics (NASDAQ: IOVA) is defying the broader trend across the space. Meanwhile, the iShares Biotechnology ETF was down by 1.6%, and the SPDR S&P Biotech ETF was in the red by 2.63% at the same point in today's trading session. While its financial results are largely immaterial at this point in its lifecycle, the company did note that it is making progress toward the possible commercial debut of lifileucel, a polyclonal tumor-infiltrating lymphocyte (TIL) therapy indicated for patients with advanced melanoma.